MyCural Therapeutics AB is developing methods and small molecules to treat aggressive cancer. The company is built on world-leading research and knowledge of the dysregulated oncoprotein MYC and methods to study its interaction with other proteins. The company has developed small molecules and is focused on developing cancer drugs for the treatment of so-called high-risk tumors.
START YEAR
2022
INVESTMENT
2022
CEO
Alina Castell
CONTACT
alina.castell@mycural.com
